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Abstract
Home blood pressure monitor (HBPM) ownership prevalence and the factors that influence it are unclear. This study aimed
to investigate factors associated with HBPM ownership among participants in the Treatment in Morning versus Evening
(TIME) hypertension study. This study is a sub-analysis of the TIME study, a randomised trial investigating the effect of
day-time versus night-time dosing of antihypertensive medication on cardiovascular outcomes in adults with hypertension.
As part of the TIME study online registration process, participants were asked to indicate whether they owned an HBPM.
A multivariable logistic regression model was constructed to determine factors associated with HBPM ownership. Of 21,104
randomised participants, 11,434 (54.2%) reported owning an HBPM. The mean age of all participants at enrolment was 67.7
± 9.3 years, 12,134 (57.5%) were male, and 8892 (42.1%) reported a current or previous history of smoking. Factors
associated with an increased likelihood of reporting HBPM owned include being male (OR:1.47; 95% CI 1.39–1.56) or
residing in a less deprived socioeconomic region (IMD Decile 6–10) (OR:1.31; 95% CI 1.23–1.40). Participants with a
history of diabetes mellitus (OR:0.74; 95% CI:0.64–0.86) or current smokers, compared to non-smokers, (OR:0.71; 95%
CI:0.62–0.82) were less likely to report owning an HBPM. This study has identified important patient factors influencing
HBPM ownership. Further qualitative research would be valuable to identify and explore potential patient-level barriers to
engagement with self-monitoring of blood pressure.
Introduction
Home blood pressure monitoring, combined with either self
or clinician-led titration of antihypertensive medication, is
increasingly recognised as an effective strategy to improve
blood pressure (BP) control in patients with hypertension
[1, 2]. Home blood pressure monitor (HBPM) measure-
ments, in comparison to clinic BP measurements, have been
reported to be more reproducible [3] and are more pre-
dictive of cardiovascular mortality [4, 5]. Other advantages
include greater convenience, the ability to make multiple
measurements over a prolonged period, avoidance of white
coat effect, and improved patient engagement with BP
management [6–8].
The prevalence of HBPM use is increasing, with estimates
that between a third and two-thirds of patients with hyper-
tension in the UK are using HBPMs for self-monitoring
[9, 10]. Global estimates for the prevalence of HBPM self-
monitoring are between 30 and 70% [11]. Meta-analyses
have shown reduced systolic and diastolic BP and overall
cost savings when an HBPM-based intervention is used in
conjunction with multidisciplinary care and education for
patients with hypertension [12, 13].
Identifying factors that may motivate or hinder patients
from owning HBPMs for self-monitoring may allow for
targeted interventions. Fear of disease progression, curios-
ity, and clinician advice have been identified as motivators
to own and use HBPMs [14]. Additionally, patient-level
demographic and medical factors (e.g. past medical and
family history) can influence ownership of medical devices
for self-monitoring. For example, in patients with a history
of stroke, the physical task of operating HBPMs was
identified as a significant deterrent for using HBPMs [15].
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This study aimed to investigate patient-level demographic,
medical, and socioeconomic factors associated with HBPM
ownership in participants of the Treatment In Morning versus
Evening (TIME) study [16]. The TIME study is a randomised
trial investigating the effect of day-time versus night-time
dosing of antihypertensive medication on cardiovascular
outcomes in adults with hypertension.
Methods
The TIME study is a prospective, randomised, open-label,
blinded end-point design remote decentralised clinical trial
investigating the effect of day-time versus night-time dosing
of antihypertensive medication on cardiovascular outcomes
in 21,104 participants with hypertension [16]. A secure
study-specific website is used to collect information directly
from participants. Patients above the age of 18, diagnosed
with hypertension and prescribed at least one anti-
hypertensive medication to be taken once daily and with a
valid email address were eligible to participate in the TIME
study. Patients taking twice daily antihypertensive therapy,
working shift patterns or involved in another clinical
trial within the last 3 months were deemed ineligible to
participate. Eligible patients enrolled in the TIME study via
a secure web platform (https://www.timestudy.co.uk/).
Invitations to participate in the TIME study were sent to
patients from primary and secondary care practices across
the UK and from databases of individuals who had pre-
viously indicated an interest in participating in research
studies. Prospective participants were invited to complete an
online form which evaluated study eligibility based on the
inclusion and exclusion criteria. Eligible participants were
then required to complete an online consent and registration
process before randomisation.
The TIME study is a registered clinical trial (EudraCT
2011-001968-21, ISRCTN18157641) with ethical approval
(East of Scotland Research Ethics Service 11/AL/0309).
Data collection
An online form, accessible via the TIME study website, was
used to collect relevant baseline information from partici-
pants regarding demographics and medical history. A
combination of check-boxes and drop-down menus were
provided for participants to indicate their responses for
variables (summarised in Table 1). The primary outcome
measurement (HBPM ownership status) was elicited as a
binary variable with two options (yes/no). All collected data
were held in a secure data server as part of the TIME study
and anonymised before analysis.
The baseline form elicited personal history of the
following health conditions: diabetes mellitus, angina,
chronic obstructive pulmonary disease, myocardial infarc-
tion, impaired kidney function, peripheral vascular disease,
arthritis, stroke and transient ischaemic attack (TIA). A
composite variable, labelled comorbidity burden was
derived to evaluate the number of comorbidities additional
to hypertension that participants reported. Participants were
classified as follows: no additional comorbidity, 1–2
comorbidities and ≥3 comorbidities.
Recruitment to the TIME study included participants
from across the UK. Individual index of multiple depriva-
tion (IMD) decile scores were derived from their residential
postal codes using the respective national guidance on
deprivation scoring detailed in Table 1. Socioeconomic
deprivation scores for each participant were collected as a
single variable, labelled IMD decile score. Subsequently,
participants were stratified into two socioeconomic groups
for analysis; more deprived (IMD decile 1–5) or less
deprived (IMD decile 6–10).
Recruitment to the TIME study began in 2011 and was
completed in 2017. Over this period, public marketing of
HBPMs increased and the awareness of self-measured BP in
the UK, improved significantly [17]. Hence, to consider the
influence of the increased awareness with time on HBPM
ownership, a variable was derived to classify participants
based on their year of registration to the TIME study
(2011–2013, 2014–2015 and 2016–2017).
Statistical analysis
Potential predictors of HBPM ownership were included in
a multivariable logistic regression model. These included:
age, gender, smoking status, BMI, individual comorbid-
ities, comorbidity burden, prescription of lipid-lowering
drugs, family history of hypertension and cardiovascular
events, number of antihypertensive medications, socio-
economic deprivation, country of residence at study
enrolment and year of registration to TIME study.
Country of residence was included in multivariable
regression analysis to adjust for country-specific differ-
ences in IMD decile scores. Results of the logistic
regression model are presented as odds ratios with asso-
ciated 95% confidence intervals. Further analysis was
performed to examine possible interactions between
gender and co-morbidities [18].
To adjust for patient error in data reporting, for vari-
ables captured via text-entry (BMI, calculated from height
and weight; systolic and diastolic BP), outlying data
points for these variables (within 0.5% of either end of the
distribution) were excluded from analysis. Before
excluding extreme data points, variables were checked for
normality of distribution using the Shapiro Wilk test. In
total, the number of excluded data points was 197, 99 and
92 entries for BMI, systolic and diastolic BP, respectively.
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All analysis was performed using RStudio (RStudio, Inc,
Massachusetts, USA; version 3.5.2 released on 20/12/




21,104 patients were randomised into the TIME study. The
majority of participants were recruited from England (n=
18,532; 87.8%). Remaining participants were from Scotland
(n= 1816; n= 8.6%), Wales (n= 750; 3.6%) and Northern
Ireland (n= 6; 0.03%). The characteristics of participants
enrolled in the TIME study are summarised in Table 2. The
mean age of all participants at enrolment was 67.7 ± 9.3
years, 12,134 (57.5%) were male, 8892 (42.1%) reported a
current or previous history of smoking and diabetes mellitus
was the most commonly reported co-morbidity affecting
2764 (13.1%) participants. Mean BMI, derived from self-
reported height and weight by 19,593 (92.8%) participants,
was 31.6 ± 6.6 kg/m2. The mean baseline self-reported
systolic and diastolic BPs were 134.9 ± 13.3 mmHg and
78.9 ± 9.4 mmHg, respectively (from 9960 (47.2%) and
9967 (47.2%) participants).
Table 1 Summary of relevant
variables collected from the
TIME study online form.
Relevant variables collected in
online form
Remarks
Selection from down menu or check-box
Date of birth –
Gender Options: Male, female
Smoking status Options: current smoker; ex-smoker; non-smoker, unknown
Co-morbidities Options: detailed in Methods
Prescription of lipid lowering
medication




Parents history of hypertension Options: yes; no, unknown
Siblings/children history of
hypertension
Options: yes; no, unknown
CV eventa in 1st degree relative
age <60
Options: yes; no, unknown
CV event in 2nd degree relative
age <50
Options: yes; no, unknown
Ownership of HBPM Options: yes; no
Free-text/string entry




Baseline self-reported blood pressure reading.
Diastolic blood
pressure (mmHg)
Residential postal-codeb Individual index of multiple deprivation (IMD) decile scores were
derived from their residential postal codes using the respective








aCardiovascular (CV) event refers to stroke, transient ischaemic attack or myocardial infarction.
bResidential postal codes were held in the secured TIME study database and only derived decile scores were
extracted for analysis in this study.
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HBPM ownership
11,434 (54.2%) participants reported owning an HBPM,
and 10,464 (49.6%) reported the model of HBPM that they
owned. In multivariable logistic regression (Table 3), fac-
tors significantly associated with a greater likelihood of
participants reporting owning an HBPM were: age of 65
and above, male, history of impaired kidney function, his-
tory of stroke or TIA, taking two or more antihypertensive
medications, parents or siblings/children with a history of
hypertension or residence in a less deprived socioeconomic
region (IMD 6–10). Participants were significantly less
likely to report owning an HBPM if they had a BMI ≥ 30
kg/m2, were current smokers, had a history of diabetes
mellitus, peripheral vascular disease or MI, were on lipid-
lowering therapy, registered for the TIME study in
2014–2015 (compared to in 2016–2017) or residence in
Scotland or Wales (compared to England) at study
enrolment.
Interactions
Male participants with a history of stroke or TIA were
found to have a reduced likelihood of owning an HBPM
(OR, 0.77; 95% CI, 0.60–0.98). However, no statistically
significant interaction was found between gender, other
comorbidities and likelihood of owning an HBPM.
Discussion
Summary
The results of this study provide practical insights into
medical and demographic factors associated with the
ownership of HBPMs by patients with hypertension in the
UK. This study has identified several factors associated
with ownership of HBPMs. Male gender, residence in less
socioeconomically deprived areas, taking two or more
antihypertensive medications daily, and a history of
impaired kidney function or either stroke or TIA were
amongst the factors associated with an increased like-
lihood of owning HBPMs. Conversely, current smokers,
participants with a medical history, including diabetes
mellitus or peripheral vascular disease or residence in
Scotland or Wales (compared to England) at study enrol-
ment were less likely to report owning an HBPM.
Strengths and limitations
A major strength of this study is that it uses self-reported
ownership of HBPM within a very large pragmatic
Table 2 Characteristics of patients recruited to the TIME study.
Overall Do not own
an HBPM
Own an HBPM
Total 21,104 9670 11,434
Age (Mean ± SD) 67.7 ± 9.3 67.5 ± 9.8 67.9 ± 8.8
Gender (%)
Male 12,134 (57.5) 5137 (53.1) 6997 (61.2)
Female 8970 (42.5) 4533 (46.9) 4437 (38.8)
Smoker (%)
Current 887 (4.2) 500 (5.2) 387 (3.4)
Non-smoker 12,078 (57.2) 5428 (56.1) 6650 (58.1)
Ex-smoker 8005 (37.9) 3662 (37.9) 4343 (38.0)
Unknown 134 (0.6) 80 (0.8) 54 (0.5)
BMI (kg/m2) (mean ± SD) 32.2 ± 7.0 31.0 ± 6.0
<30 9116 (43.2) 3771 (39.0) 5345 (46.7)
≥30 (Obese) 10,477 (49.6) 5051 (52.2) 5426 (47.5)
Unknown 1511 (7.2) 848 (8.7) 663 (5.8)
Co-morbidities (%)
Diabetes 2764 (13.1) 1492 (15.4) 1272 (11.1)
Angina 779 (3.7) 375 (3.9) 404 (3.5)
COPD 615 (2.9) 315 (3.3) 300 (2.6)
Impaired kidney function 681 (3.2) 289 (3.0) 392 (3.4)
Arthritis 1997 (9.5) 945 (9.8) 1052 (9.2)
Peripheral vascular disease 323 (1.5) 175 (1.8) 148 (1.3)
Myocardial Infarction 985 (4.7) 503 (5.2) 482 (4.2)
Stroke/TIA 1239 (5.9) 527 (5.4) 712 (6.2)
Co-morbidity burden (%)
No co-morbidity 14,147 (67.0) 6283 (65.0) 7864 (68.8)
1–2 co-morbidities 6438 (30.5) 3122 (32.3) 3316 (29.0)
≥3 co-morbidities 519 (2.5) 265 (2.7) 254 (2.2)
Prescribed lipid lowering
therapy (%)
7397 (35.1) 3393 (35.1) 4004 (35.0)
Family history (%)
Parents history of HTN 12,366 (58.6) 5526 (57.1) 6840 (59.8)
Siblings/children HTN
history
5942 (28.1) 2623 (27.1) 3319 (29.0)
CV event in 1st degree
relative age <60
5049 (23.9) 2342 (24.2) 2707 (23.7)
CV event in 2nd degree
relative age <50
1716 (8.1) 833 (8.6) 883 (7.7)
No. of antihypertensive medications (%)
1 11,845 (56.1) 5681 (58.7) 6164 (53.9)
≥2 8769 (41.6) 3740 (38.7) 5029 (44.0)




5953 (28.2) 3080 (31.9) 2873 (25.1)
Less deprived (IMD
Decile 6–10)
14,898 (70.6) 6457 (66.8) 8441 (73.8)
Unknown 253 (1.2) 133 (1.4) 120 (1.1)
Country of residence at enrolment (%)
England 18,532 (87.8) 8277 (85.6) 10,255 (89.7)
Scotland 1816 (8.6) 1004 (10.4) 812 (7.1)
Wales 750 (3.6) 386 (4.0) 364 (3.2)
Northern Ireland 6 (0.0) 3 (0.0) 3 (0.0)
Year of registration to trial
2011–2013 396 (1.9) 178 (1.9) 218 (1.9)
2014–2015 10,871 (51.5) 5187 (53.6) 5684 (49.7)
2016–2017 9837 (46.6) 4305 (44.5) 5532 (48.4)
COPD Chronic obstructive pulmonary disease, TIA Transient ischaemic
attack, HTN hypertension, IMD index of multiple deprivation, CV
Cardiovascular.
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randomised clinical trial. The study population comprises
UK adults with diagnosed hypertension, the main target
population for HBPM-based interventions. This study does
have several limitations. Firstly, it relies solely on patient-
reported data, the accuracy of which is not verifiable.
Several data fields had erroneous entries which were
excluded from subsequent analyses. Patient demographic
factors, such as educational attainment and monthly income,
which are known predictors of patient engagement with
medical devices for self-monitoring, are not collected in the
TIME study [19]. This study also relies on data from par-
ticipants who have opted to be part of an online clinical
trial: it is known that clinical trials have an inherent selec-
tion bias towards people who are more engaged with their
health and, we might assume, would be more likely to have
engaged with self-monitoring of their hypertension. The
TIME study’s online-only nature may also reduce gen-
eralisability as participants were required to have an email
address and internet access. It is also unclear whether the
statistically significant associations with HBPM ownership
observed in this study would remain valid for the wider
population, including shift-workers and people taking their
antihypertensive medication more than once a day. The
general practitioner (GP) role in influencing HBPM own-
ership was not investigated in this study. The GP-patient
relationship, GPs’ medical advice and their perception of
the utility of home BP measurement can influence patients’
involvement in self-monitoring of their BP [20].
Comparison with existing literature
In the TIME study cohort, the rate of HBPM ownership was
found to be 54.2%; this is comparable with previously
observed HBPM ownership rates which range from 22.8 to
61.7% [11, 19, 21–23]. International differences in patient
education on self-monitoring BP and accessibility of
HBPMs for private purchase are potential contributing fac-
tors to the wide range of HBPM ownership rates observed.
Indeed, in less-developed or resource-poor countries, the
difficulty of accessing reliable and affordable HBPMs is a
recognised challenge [21]. Older age, higher educational
status, higher socioeconomic class, non-smoking status, and
family history of hypertension are all factors found to be
associated with HBPM ownership in previous studies. There
is some variation in the influence of gender on HBPM
ownership across published literature. However, men have
been frequently found to be more likely to own an HBPM,
consistent with our findings. Factors associated with poorer
health habits, such as smoking and obesity, were associated
with a reduced likelihood of owning an HBPM in this study.
Although this association seems intuitive, in a survey in
Table 3 Logistic regression of factors associated with HBPM
ownership amongst participants in the TIME study.
Univariate analysis Adjusted analysis
OR 95% CI OR 95% CI
Age
<65 years Reference Reference
≥65 years 1.15 1.08–1.22 1.1 1.03–1.17
Unknown 0.91 0.70–1.19 0.95 0.73–1.25
Gender
Female Reference Reference
Male 1.39 1.32–1.47 1.47 1.39–1.56
BMI (kg/m2)
<30 Reference Reference
≥30 (Obese) 0.76 0.72–0.80 0.79 0.74–0.84
Unknown 0.55 0.49–0.62 0.64 0.57–0.72
Smoking status
Non-smoker Reference Reference
Current 0.63 0.55–0.72 0.71 0.62–0.82
Ex-smoker 0.97 0.91–1.02 0.98 0.92–1.04
Unknown 0.55 0.39–0.78 0.68 0.47–0.97
Co-morbidity
Diabetes mellitus 0.69 0.63–0.74 0.74 0.64–0.86
Angina 0.91 0.79–1.05 1 0.84–1.21
COPD 0.8 0.68–0.94 0.9 0.74–1.09
Impaired kidney function 1.15 0.99–1.35 1.26 1.04–1.52
Arthritis 0.94 0.85–1.03 1.07 0.92–1.24
PVD 0.71 0.57–0.89 0.77 0.60–0.98
Myocardial Infarction 0.8 0.71–0.91 0.82 0.69–0.97
Stroke/TIA 1.15 1.03–1.29 1.23 1.04–1.45
Reported co-morbidity burden
No co-morbidity Reference Reference
1–2 co-morbidities 0.85 0.80–0.90 0.95 0.82–1.10
≥3 co-morbidities 0.77 0.64–0.91 0.96 0.64–1.42
On lipid lowering therapy 0.86 0.81–0.91 0.84 0.78–0.90
CV event in 1st degree relative age <60 0.96 0.91–1.03 0.99 0.93–1.06
CV event in 2nd degree relative
age <50
0.88 0.79–0.97 0.94 0.85–1.04
Parents with history of HTN 1.1 1.04–1.16 1.12 1.05–1.20
Siblings/children with history of HTN 1.08 1.01–1.15 1.1 1.02–1.18
No. of anti-hypertensive medications
1 Reference Reference
≥2 1.24 1.17–1.31 1.25 1.17–1.32
Unknown 0.89 0.74–1.07 0.94 0.77–1.15
Socioeconomic deprivation
More deprived (IMD Decile 1–5) Reference Reference
Less deprived (IMD Decile 6–10) 1.4 1.32–1.49 1.31 1.23–1.40
Unknown 0.97 0.75–1.24 1.16 0.89–1.51
Country of residence at enrolment
England Reference Reference
Scotland 0.65 0.59–0.72 0.64 0.58–0.71
Wales 0.76 0.66–1.88 0.74 0.64–0.86
Northern Ireland 0.81 0.15–4.36 0.98 0.18–5.34
Year of registration
2016–2017 Reference Reference
2014–2015 0.85 0.81–0.90 0.84 0.80–0.89
2011–2013 0.95 0.78–1.17 1.07 0.86–1.34
COPD Chronic obstructive pulmonary disease, TIA transient ischae-
mic attack, HTN hypertension, IMD index of multiple deprivation, CV
cardiovascular.
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Pakistan involving 405 hypertensive adults, those who
reported a lack of exercise were, contrastingly, more likely
to own HBPMs [11]. The authors of that study, Zahid et al.
proposed that those patients, aware of their poorer health
habits, were more likely, as a precautionary measure, to self-
monitor their BP [11]. It is not known whether issues
associated with obesity, such as the need for a larger BP cuff
size, which may not come as standard with a machine, or
increased discomfort using BP cuffs dissuade patients from
acquiring HBPM [24].
Diabetes mellitus, peripheral vascular disease and pre-
vious MI were co-morbidities significantly associated with a
reduced likelihood of HBPM ownership in this study. In
these patient groups, there is evidence of advantages in self-
monitoring BP. For example, in people who have a history
of MI or diabetes mellitus, self-measured BP readings have
been shown to be predictive of complications [25–27].
However, the burden of chronic conditions and associated
medications may negatively impact patients’ engagement
with their healthcare, possibly explaining lower ownership
of HBPMs. This hypothesis is supported by the reduced
likelihood of HBPM ownership in patients on additional
medication (lipid-lowering drugs) within the TIME study.
However, further studies would be required in this subgroup
of patients to validate this proposed association [28].
A history of stroke or TIA was associated with an
increased likelihood of owning HBPMs in our study.
Indeed, in a previous study, a serious health event asso-
ciated with hypertension, such as stroke, was identified as a
motivator for patients to begin self-monitoring BP [21].
However, it must be acknowledged that residual physical
disability following a stroke, particularly of the upper limbs,
may impair the ability to use HBPMs. Interestingly, men
with a history of stroke or TIA were less likely to report
owning an HBPM. This association is likely due to pro-
portionately higher engagement rates with HBPM owner-
ship amongst females with a history of stroke or TIA
(56.2%, 241/429). In a qualitative study exploring patient
experiences of receiving a diagnosis of chronic kidney
disease, dialysis was one of the most commonly reported
sources of fear [29]. With adequate control of BP delaying
the need for renal replacement therapy, this may explain the
increased adoption of HBPMs in patients with impaired
kidney function observed in this study [30, 31].
Implications for future research and practice
In this study, ownership of HBPMs was the primary out-
come measurement. The frequency of HBPM use (e.g.
weekly, monthly) amongst hypertensive patients who own
their own devices was not evaluated. Significant variations
in frequency of home BP measurement ranging from once
daily to less than monthly have previously been reported
[1]. The frequency of self-measured BP readings required to
observe clinically significant improvement in health out-
comes remains unclear. However, a regime of twice each
morning and evening for the first week of the month was
adopted in the TASMINH4 trial which reported sig-
nificantly lower BP associated with regular HBPM use. One
of the key recommendations in the recent Cross-Party
Group report on hypertension in Scotland [32] was to scope
the feasibility and cost-effectiveness of the widespread
provision of BP monitors to people with high BP and
determine the most appropriate mechanism to deliver this.
Qualitative research to explore factors which may prevent a
patient from using an HBPM regularly and acting upon the
results would be valuable to inform any future imple-
mentation of BP self-monitoring. Perhaps in the future,
HBPM devices will be prescribed for patients.
The prevalence of HBPM ownership in hypertensive
patients recruited to the TIME study was approximately half.
HBPM ownership among hypertensive patients is increasing;
older males, from less deprived socioeconomic regions, with a
family history of hypertension, are the demographic most
likely to report HBPM ownership. Previous stroke or TIA was
associated with an increased likelihood of reporting HBPM
ownership within the TIME study cohort. Conversely, chronic
conditions such as diabetes mellitus and peripheral vascular
disease, and previous MI were associated with a reduced
likelihood of HBPM ownership. Further qualitative research
would be valuable to identify and explore potential patient-
level barriers to engagement with self-monitoring of BP. This
may guide prospective evaluation of more targeted interven-
tions to improve ownership and use of HBPMs for self-
monitoring of BP.
Summary
What is known about topic
● There is increasing evidence that home blood pressure
monitoring is an effective strategy to improve BP
control in patients with hypertension.
● HBPM ownership prevalence and the factors that
influence it are unclear.
What this study adds
● Within the TIME study cohort, older males, people from
less deprived areas, and those with a family history
of hypertension, were most likely to report HBPM
ownership.
T. Anbarasan et al.
● Chronic conditions such as diabetes mellitus, ischaemic
heart disease and peripheral vascular disease, were
associated with a reduced likelihood of ownership.
● Recognition of factors associated with HBPM owner-
ship may guide more targeted interventions to promote
its use.
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